Lilly to Initiate GGG Ph1 DDI Study
A Lilly-sponsored Ph1 trial has been observed evaluating the effects of Lilly’s GGG tri-agonist (GLP/GCG/GIP) on drug-drug interactions with midazolam, warfarin, and caffeine (view CT.gov record). Below FENIX provides additional details from the trial record as well as insight into how Lilly’s GGG DDI trial is different from prior DDI studies with the incretin class.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.